Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Breast Cancer Resistance Protein 1 Knockout Mice

The dietary polyphenols genistein and daidzein are potent effectors of biological processes. The plasma profile of both isoflavones is governed by the presence of phase II conjugates, mainly glucuronides and sulfates. Breast cancer resistance protein (ABCG2/BCRP) interacts with genistein and daidzein, which are among the natural substrates of the transporter and competitively inhibit ABCG2-mediated drug efflux. ABCG2/BCRP can also transport glucuronide and sulfate conjugates. In this study, we analyzed the plasma levels of aglycones and derived conjugated metabolites, glucuronides, and sulfates, after intragastric administration of these isoflavones to wild-type and Bcrp1(−/−) knockout mice. The results show that overall plasmatic profile is mainly governed by sulfate and glucuronide derivatives, the concentration of which was significantly increased (7- to 10-fold) in Bcrp1(−/−) mice. The total AUC h nM (0–180 min), as the sum of aglycones, glucuronides, and sulfates, was 901 ± 207 in wild-type mice versus 4988 ± 508 in Bcrp1(−/−) mice after genistein administration (50 mg/kg b.wt.); 584.3 ± 90 in wild-type mice versus 4012 ± 612 in Bcrp1(−/−) after daidzein administration (50 mg/kg); and 926 ± 140 in wild-type mice versus 5174 ± 696 in Bcrp1(−/−) after genistein+daidzein administration (25 + 25 mg/kg). Therefore, our results indicate a direct and conclusive Bcrp1 efflux action on phase II metabolites of these isoflavones in vivo and suggest a possible novel concept for ABCG2/BCRP as part of metabolism-driven efflux transport of these conjugates.

[1]  G. Merino,et al.  Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. , 2010, Journal of agricultural and food chemistry.

[2]  Y. Sugimoto,et al.  Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure–activity relationship , 2007, Cancer Chemotherapy and Pharmacology.

[3]  Yuichi Sugiyama,et al.  Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens , 2007, Molecular Pharmacology.

[4]  V. Tam,et al.  Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. , 2009, Molecular pharmaceutics.

[5]  Margaret M. Manson,et al.  Mechanisms of combined action of different chemopreventive dietary compounds , 2008, European journal of nutrition.

[6]  Z. Zuo,et al.  Intestinal and hepatic glucuronidation of flavonoids. , 2007, Molecular pharmaceutics.

[7]  Y. Sugimoto,et al.  Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics , 2005, Cancer science.

[8]  S. Barnes,et al.  Intestinal uptake and biliary excretion of the isoflavone genistein in rats. , 1997, The Journal of nutrition.

[9]  P. Blondeel,et al.  Disposition of soy isoflavones in normal human breast tissue. , 2010, The American journal of clinical nutrition.

[10]  D. Doerge,et al.  Absolute bioavailability of isoflavones from soy protein isolate-containing food in female BALB/c mice. , 2010, Journal of agricultural and food chemistry.

[11]  Gary Williamson,et al.  Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. , 2005, The American journal of clinical nutrition.

[12]  G. Merino,et al.  In Vivo Inhibition of BCRP/ABCG2 Mediated Transport of Nitrofurantoin by the Isoflavones Genistein and Daidzein: A Comparative Study in Bcrp1 −/− Mice , 2010, Pharmaceutical Research.

[13]  V. Tam,et al.  DISPOSITION OF FLAVONOIDS VIA RECYCLING: COMPARISON OF INTESTINAL VERSUS HEPATIC DISPOSITION , 2005, Drug Metabolism and Disposition.

[14]  V. Tam,et al.  Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties , 2006, Drug Metabolism and Disposition.

[15]  Liliana Jiménez,et al.  Polyphenols: food sources and bioavailability. , 2004, The American journal of clinical nutrition.

[16]  J. Groten,et al.  Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Y. Sawada,et al.  Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. , 2010, Drug metabolism and pharmacokinetics.

[18]  Q. Mei,et al.  Dose-dependent absorption, metabolism, and excretion of genistein in rats. , 2008, Journal of agricultural and food chemistry.

[19]  M. Hu,et al.  Natural polyphenol disposition via coupled metabolic pathways , 2007, Expert opinion on drug metabolism & toxicology.

[20]  P. Murphy,et al.  Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. , 1999, The Journal of nutrition.

[21]  Y. Sugimoto,et al.  Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.

[22]  J. Lampe,et al.  Interindividual differences in phytochemical metabolism and disposition. , 2007, Seminars in cancer biology.

[23]  R. Singh,et al.  Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. , 2009, Molecular pharmaceutics.

[24]  M. Hu,et al.  Breast Cancer Resistance Protein (BCRP) and Sulfotransferases Contribute Significantly to the Disposition of Genistein in Mouse Intestine , 2010, The AAPS Journal.